Testim® Gel: Review of Clinical Data

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

The PSA Era is not Over for Prostate Cancer

Prostate Cancer 2008: Challenges in Diagnosis and Management

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Counselling the Prostate Cancer Patient

The PSA Era is not Over for Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Richard C. Harkaway European Urology Supplements

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care Fred Saad, Carl Olsson, Claude C. Schulman

Risk Factors for the Development of Bone Metastases in Prostate Cancer

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Yong-jiang Hei European Urology Supplements

The Importance of Testosterone Control in Prostate Cancer

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Optimal Testosterone Control and Eligard®

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Neal Shore European Urology Supplements

Long-Term Hormonal Therapy: Who Would Benefit?

Nicholas D. James, Jim W. Growcott European Urology Supplements

The Hallmarks of BPH Progression and Risk Factors

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Pharmacotherapy in Stress and Mixed Incontinence

Christian Stief European Urology Supplements

European Urology is “Your” Journal

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.

Preclinical Profile of Zoledronic Acid in Prostate Cancer Models

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer 2008: Challenges in Diagnosis and Management

Martin Michel, Jean de la Rosette European Urology Supplements

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Richard Berges European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

Bob Djavan European Urology Supplements

Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid Theresa A. Guise,

Androgen Receptor Mediated Growth of Prostate (Cancer)

Complex Mechanisms in Prostatic Inflammatory Response

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation Martin.

The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study Bob Djavan,

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects Martin C. Michel, Cees Korstanje, Walter.

C.G Roehrborn, T McNicholas European Urology Supplements

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Hormone Therapy: Improving Therapy Decisions and Monitoring

The Impact of Premature Ejaculation on Partners and Relationships

Emmanuel Chartier-Kastler, Andrea Tubaro European Urology Supplements

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Bone 2014;69C:89 (Fig. 2) Reproduced from Bone, 69C:89-97, Copyright (2014), with permission from Elsevier.

J Bone Miner Res 2014;doi: /jbmr.2325 (Fig. 2)

Michael Marberger European Urology Supplements

Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? B. Tombal European Urology.

Introduction European Urology Supplements

Presentation transcript:

Testim® Gel: Review of Clinical Data Tom A. McNicholas European Urology Supplements Volume 4, Issue 6, Pages 24-30 (August 2005) DOI: 10.1016/j.eursup.2005.05.005 Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 1 Total serum testosterone levels over 48hours following a single dose of Testim® Gel 50mg or AndroGel®/Testogel® 50mg (N=29) [2]. (Reproduced with permission [2]. Copyright© 2003 John Wiley and Sons Ltd.). European Urology Supplements 2005 4, 24-30DOI: (10.1016/j.eursup.2005.05.005) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 2 Positive and negative mood scores (on a 0–7 Likert-type categorical scale) during 12 months of treatment with Testim® Gel 50mg or 100mg, showing both dosage groups combined (N=371) [6]. (Copyright© MedReviews, LLC. Reproduced with permission of MedReviews, LLC. Reviews in Urology is a copyrighted publication of MedReviews, LLC. All rights reserved.). European Urology Supplements 2005 4, 24-30DOI: (10.1016/j.eursup.2005.05.005) Copyright © 2005 Elsevier B.V. Terms and Conditions

Fig. 3 Mean percentage change in bone mineral density of the lumbar spine from baseline during 12 months of treatment with Testim® Gel 50mg or 100mg, showing both dosage groups combined (N=371) [6]. (Copyright© MedReviews, LLC. Reproduced with permission of MedReviews, LLC. Reviews in Urology is a copyrighted publication of MedReviews, LLC. All rights reserved.). European Urology Supplements 2005 4, 24-30DOI: (10.1016/j.eursup.2005.05.005) Copyright © 2005 Elsevier B.V. Terms and Conditions